HighTower Advisors LLC Has $640,000 Position in RxSight, Inc. (NASDAQ:RXST)

HighTower Advisors LLC increased its holdings in shares of RxSight, Inc. (NASDAQ:RXST) by 37.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,013 shares of the company’s stock after purchasing an additional 3,571 shares during the period. HighTower Advisors LLC’s holdings in RxSight were worth $640,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the business. Brown Capital Management LLC acquired a new position in shares of RxSight in the third quarter valued at approximately $26,813,000. Marshall Wace LLP bought a new position in RxSight during the 2nd quarter worth about $19,512,000. Driehaus Capital Management LLC increased its holdings in RxSight by 74.9% during the 2nd quarter. Driehaus Capital Management LLC now owns 706,162 shares of the company’s stock worth $42,490,000 after purchasing an additional 302,367 shares in the last quarter. Baillie Gifford & Co. raised its stake in shares of RxSight by 438.8% in the 2nd quarter. Baillie Gifford & Co. now owns 358,215 shares of the company’s stock valued at $21,554,000 after purchasing an additional 291,733 shares during the period. Finally, William Blair Investment Management LLC bought a new stake in shares of RxSight in the second quarter valued at about $14,942,000. 78.78% of the stock is owned by institutional investors.

RxSight Trading Up 2.7 %

NASDAQ RXST opened at $38.19 on Friday. The firm’s fifty day moving average price is $46.08 and its two-hundred day moving average price is $50.25. RxSight, Inc. has a 1 year low of $34.92 and a 1 year high of $66.54. The firm has a market capitalization of $1.54 billion, a P/E ratio of -46.01 and a beta of 1.11.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Needham & Company LLC reiterated a “buy” rating and set a $66.00 price objective on shares of RxSight in a report on Friday, September 13th. Jefferies Financial Group began coverage on shares of RxSight in a research note on Tuesday, October 29th. They set a “buy” rating and a $72.00 price target for the company. Wells Fargo & Company reissued an “equal weight” rating and issued a $42.00 price objective (down previously from $56.00) on shares of RxSight in a research report on Wednesday, December 11th. Finally, UBS Group initiated coverage on shares of RxSight in a research report on Friday, December 6th. They issued a “buy” rating and a $52.00 target price for the company. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $62.13.

Insider Activity

In other RxSight news, Director Shweta Maniar sold 3,782 shares of the company’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $45.88, for a total value of $173,518.16. Following the transaction, the director now directly owns 10,902 shares in the company, valued at $500,183.76. The trade was a 25.76 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Ilya Goldshleger sold 3,100 shares of the firm’s stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $52.67, for a total transaction of $163,277.00. Following the sale, the insider now owns 42,246 shares of the company’s stock, valued at approximately $2,225,096.82. This represents a 6.84 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 62,707 shares of company stock valued at $3,037,386. 9.36% of the stock is owned by company insiders.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.